Table 2.
Sex differences in patients with AF-HF with and without CA
| All patients with AF-HF (N = 101,931) N (%) |
Patients with CA (N = 432) N (%) |
|||
|---|---|---|---|---|
| Male 49,528 (48.6) |
Female 52,403 (51.4) |
Male 322 (74.4) |
Female 110 (25.6)∗ |
|
| Median age (IQR), y | 78.5 (71.8-84.3) | 82.6 (76.3-87.8)∗ | 66.5 (58.4-71.6) | 65.0 (60.6-73.0) |
| <65 | 4385 (9.0) | 2339 (4.5) | 140 (43.5) | 54 (49.1) |
| 65-75 | 13,350 (27.0) | 8776 (16.8) | 143 (44.4) | 36 (32.7) |
| ≥75 | 31,793 (64.1) | 41,288 (78.8) | 39 (12.1) | 20 (18.2) |
| Hypertension | 14,922 (30.1) | 17,655 (33.7)∗ | 83 (25.5) | 27 (24.6) |
| Diabetes mellitus | 8820 (17.8) | 8012 (15.3)∗ | 51 (15.8) | 16 (14.5) |
| Coronary artery disease | 14,905 (30.1) | 12,418 (23.7)∗ | 74 (22.7) | 15 (13.6)∗ |
| Prior myocardial infarction | 6637 (13.4) | 4827 (9.2)∗ | 42 (13.0) | 7 (6.4) |
| Valvular disease | 12,029 (24.3) | 15,802 (30.2)∗ | 98 (30.3) | 40 (36.0) |
| Valve replacement | 1439 (2.9) | 1408 (2.7)∗ | 5 (1.6) | 2 (1.8) |
| Chronic obstructive pulmonary disease | 9071 (18.3) | 7434 (14.2)∗ | 29 (9.0) | 4 (3.6) |
| Chronic renal failure | 7679 (15.5) | 6777 (12.9)∗ | 28 (8.7) | 3 (2.7)∗ |
| Prior stroke (including TIA) | 906 (1.8) | 1189 (2.3)∗ | 1 (0.3) | 0 (0.0) |
| Liver disease | 1258 (2.5) | 983 (1.9)∗ | 7 (2.2) | 0 (0.0) |
| Vascular disease | 6662 (13.5) | 5334 (10.2)∗ | 17 (5.3) | 4 (3.6) |
| Prior major bleeding | 2514 (5.1) | 1641 (3.1)∗ | 6 (1.9) | 2 (1.8) |
| Implantable cardioverter defibrillator | 2091 (4.2) | 475 (0.9)∗ | 70 (21.7) | 6 (5.5)∗ |
| Cardiac resynchronization therapy | 5447 (11.0) | 4161 (7.9)∗ | 73 (22.7) | 10 (9.1)∗ |
| Median CHA2DS2-VASc score | 3 (3-4) | 4 (4-5)∗ | 2 (1-3) | 3 (2-4)∗ |
| Median HAS-BLED score | 1 (1-2) | 1 (1-2)∗ | 1 (0-1) | 1 (0-1) |
The baseline table presents the distribution of patient characteristics at cohort entry and does not include the comorbidities and devices acquired during the follow-up period, which is included in the analysis.
AF, atrial fibrillation; CA, catheter ablation; HF, heart failure; TIA, transient ischemic attack.
∗
P values of < 0.05 are considered statistically significant. P values compare male and female patients.